PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions

Tian Zhang, Shiva K. Das, Diane R. Fels, Katherine S Hansen, Terence Z. Wong, Mark W. Dewhirst, Gordana Vlahovic

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE. Hypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical, prostate, and rectal cancers. Unlike the others, lung cancers present a unique challenge in measuring hypoxia, with invasive biopsies and higher rates of complications. Noninvasive imaging studies detecting hypoxia using isotopes of copper-diacetyl-bis(N4- methylthiosemicarbazone) (62Cu-ATSM) have predicted prognosis and treatment outcomes in some small feasibility trials. These images, however, may not identify all areas of hypoxia. Hence, we hypothesize that the addition of another PET imaging agent, copper-pyruvaldehyde- bis(N4-methylthiosemicarbazone) (62Cu-PTSM), which can detect areas of perfusion, can augment the information obtained in 62Cu-ATSM PET scans. SUBJECTS AND METHODS. To characterize tumors on the basis of both perfusion and hypoxia, 10 patients were studied using both 62Cu-ATSM and 62Cu-PTSM PET scans. In addition, proteomic arrays looking at specific proangiogenic, survival, and proinflammatory targets were assessed. RESULTS. Six of 10 patients had evaluable PET scans. Our initial experience of characterizing lung tumor hypoxia using 62Cu-ATSM and 62Cu-PTSM PET scans showed that visualization of areas with hypoxia normalized for perfusion is feasible. All studied tumors exhibited some hypoxia. Despite the small sample size, a positive relationship was noted between epidermal growth factor levels and 62Cu-ATSM-detected hypoxia. CONCLUSION. This initial series of 62Cu-ATSM and 62Cu-PTSM PET scans shows that evaluating lung masses by visualizing hypoxia and perfusion is a feasible and novel technique to provide more information. Further investigation is warranted to assess the potential role of 62Cu-ATSM and 62Cu-PTSM PET techniques combined with proteomics as alternatives to invasive biopsy techniques in clinical care.

Original languageEnglish (US)
JournalAmerican Journal of Roentgenology
Volume201
Issue number5
DOIs
StatePublished - Nov 2013

Fingerprint

Perfusion
Lung
Positron-Emission Tomography
Proteomics
Copper
Lung Neoplasms
Pyruvaldehyde
Biopsy
Hypoxia
Diacetyl
Neoplasms
Rectal Neoplasms
Epidermal Growth Factor
Isotopes
Uterine Cervical Neoplasms
Sample Size
Prostatic Neoplasms
Survival

Keywords

  • Hypoxia
  • Lung tumor
  • Perfusion
  • PET

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. / Zhang, Tian; Das, Shiva K.; Fels, Diane R.; Hansen, Katherine S; Wong, Terence Z.; Dewhirst, Mark W.; Vlahovic, Gordana.

In: American Journal of Roentgenology, Vol. 201, No. 5, 11.2013.

Research output: Contribution to journalArticle

Zhang, Tian ; Das, Shiva K. ; Fels, Diane R. ; Hansen, Katherine S ; Wong, Terence Z. ; Dewhirst, Mark W. ; Vlahovic, Gordana. / PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. In: American Journal of Roentgenology. 2013 ; Vol. 201, No. 5.
@article{c69160b5cd064ca5b1789a905b5ddd52,
title = "PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions",
abstract = "OBJECTIVE. Hypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical, prostate, and rectal cancers. Unlike the others, lung cancers present a unique challenge in measuring hypoxia, with invasive biopsies and higher rates of complications. Noninvasive imaging studies detecting hypoxia using isotopes of copper-diacetyl-bis(N4- methylthiosemicarbazone) (62Cu-ATSM) have predicted prognosis and treatment outcomes in some small feasibility trials. These images, however, may not identify all areas of hypoxia. Hence, we hypothesize that the addition of another PET imaging agent, copper-pyruvaldehyde- bis(N4-methylthiosemicarbazone) (62Cu-PTSM), which can detect areas of perfusion, can augment the information obtained in 62Cu-ATSM PET scans. SUBJECTS AND METHODS. To characterize tumors on the basis of both perfusion and hypoxia, 10 patients were studied using both 62Cu-ATSM and 62Cu-PTSM PET scans. In addition, proteomic arrays looking at specific proangiogenic, survival, and proinflammatory targets were assessed. RESULTS. Six of 10 patients had evaluable PET scans. Our initial experience of characterizing lung tumor hypoxia using 62Cu-ATSM and 62Cu-PTSM PET scans showed that visualization of areas with hypoxia normalized for perfusion is feasible. All studied tumors exhibited some hypoxia. Despite the small sample size, a positive relationship was noted between epidermal growth factor levels and 62Cu-ATSM-detected hypoxia. CONCLUSION. This initial series of 62Cu-ATSM and 62Cu-PTSM PET scans shows that evaluating lung masses by visualizing hypoxia and perfusion is a feasible and novel technique to provide more information. Further investigation is warranted to assess the potential role of 62Cu-ATSM and 62Cu-PTSM PET techniques combined with proteomics as alternatives to invasive biopsy techniques in clinical care.",
keywords = "Hypoxia, Lung tumor, Perfusion, PET",
author = "Tian Zhang and Das, {Shiva K.} and Fels, {Diane R.} and Hansen, {Katherine S} and Wong, {Terence Z.} and Dewhirst, {Mark W.} and Gordana Vlahovic",
year = "2013",
month = "11",
doi = "10.2214/AJR.12.9698",
language = "English (US)",
volume = "201",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "5",

}

TY - JOUR

T1 - PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions

AU - Zhang, Tian

AU - Das, Shiva K.

AU - Fels, Diane R.

AU - Hansen, Katherine S

AU - Wong, Terence Z.

AU - Dewhirst, Mark W.

AU - Vlahovic, Gordana

PY - 2013/11

Y1 - 2013/11

N2 - OBJECTIVE. Hypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical, prostate, and rectal cancers. Unlike the others, lung cancers present a unique challenge in measuring hypoxia, with invasive biopsies and higher rates of complications. Noninvasive imaging studies detecting hypoxia using isotopes of copper-diacetyl-bis(N4- methylthiosemicarbazone) (62Cu-ATSM) have predicted prognosis and treatment outcomes in some small feasibility trials. These images, however, may not identify all areas of hypoxia. Hence, we hypothesize that the addition of another PET imaging agent, copper-pyruvaldehyde- bis(N4-methylthiosemicarbazone) (62Cu-PTSM), which can detect areas of perfusion, can augment the information obtained in 62Cu-ATSM PET scans. SUBJECTS AND METHODS. To characterize tumors on the basis of both perfusion and hypoxia, 10 patients were studied using both 62Cu-ATSM and 62Cu-PTSM PET scans. In addition, proteomic arrays looking at specific proangiogenic, survival, and proinflammatory targets were assessed. RESULTS. Six of 10 patients had evaluable PET scans. Our initial experience of characterizing lung tumor hypoxia using 62Cu-ATSM and 62Cu-PTSM PET scans showed that visualization of areas with hypoxia normalized for perfusion is feasible. All studied tumors exhibited some hypoxia. Despite the small sample size, a positive relationship was noted between epidermal growth factor levels and 62Cu-ATSM-detected hypoxia. CONCLUSION. This initial series of 62Cu-ATSM and 62Cu-PTSM PET scans shows that evaluating lung masses by visualizing hypoxia and perfusion is a feasible and novel technique to provide more information. Further investigation is warranted to assess the potential role of 62Cu-ATSM and 62Cu-PTSM PET techniques combined with proteomics as alternatives to invasive biopsy techniques in clinical care.

AB - OBJECTIVE. Hypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical, prostate, and rectal cancers. Unlike the others, lung cancers present a unique challenge in measuring hypoxia, with invasive biopsies and higher rates of complications. Noninvasive imaging studies detecting hypoxia using isotopes of copper-diacetyl-bis(N4- methylthiosemicarbazone) (62Cu-ATSM) have predicted prognosis and treatment outcomes in some small feasibility trials. These images, however, may not identify all areas of hypoxia. Hence, we hypothesize that the addition of another PET imaging agent, copper-pyruvaldehyde- bis(N4-methylthiosemicarbazone) (62Cu-PTSM), which can detect areas of perfusion, can augment the information obtained in 62Cu-ATSM PET scans. SUBJECTS AND METHODS. To characterize tumors on the basis of both perfusion and hypoxia, 10 patients were studied using both 62Cu-ATSM and 62Cu-PTSM PET scans. In addition, proteomic arrays looking at specific proangiogenic, survival, and proinflammatory targets were assessed. RESULTS. Six of 10 patients had evaluable PET scans. Our initial experience of characterizing lung tumor hypoxia using 62Cu-ATSM and 62Cu-PTSM PET scans showed that visualization of areas with hypoxia normalized for perfusion is feasible. All studied tumors exhibited some hypoxia. Despite the small sample size, a positive relationship was noted between epidermal growth factor levels and 62Cu-ATSM-detected hypoxia. CONCLUSION. This initial series of 62Cu-ATSM and 62Cu-PTSM PET scans shows that evaluating lung masses by visualizing hypoxia and perfusion is a feasible and novel technique to provide more information. Further investigation is warranted to assess the potential role of 62Cu-ATSM and 62Cu-PTSM PET techniques combined with proteomics as alternatives to invasive biopsy techniques in clinical care.

KW - Hypoxia

KW - Lung tumor

KW - Perfusion

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84886458040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886458040&partnerID=8YFLogxK

U2 - 10.2214/AJR.12.9698

DO - 10.2214/AJR.12.9698

M3 - Article

VL - 201

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 5

ER -